A Study Of Recombinant VMIP-Ⅱ Affect SIV/HIV Specific CD8～+T Lymphocytes Antivirus Immunity Functions

ObjectiveCytotoxic function mediated by Virus-specific CD8~+T lymphocytes play a key anti-viruses role in HIV infections. The gene expression produce viral macrophage inflammatory protein-Ⅱ (vMIP-Ⅱ ) has been validated as anti-HIV medicine—entry inhibitor through competition combining chemokine receptors(CCR5/CXCR4).This experiment device was based on multi-chemokine receptors expressing on T lymphocytes and the character that vMIP-Ⅱ may combine these receptors, and studied the effect that vMIP-Ⅱ can regulate anti-viral immunity function of CD8~+ T lymphocytes, accordingly clarified the anti-HIV immunological mechanism of it. MethordsHere we adopted a method of MTT assay and flow cytometry technology examining the proliferation of SIV specific CD8~+T lymphocytes before and after vMIP-Ⅱ injection, Checked and measured the effect of memory and effector CD8~+T lymphocytes subsets—CD8~+CD28~+ and CD8~+CD28~-T lymphocytes differentiation; Constructing HIV antigen specific CTL through dentritic cells presenting antigens in vitro, we examined that vMIP-Ⅱ affected proliferation, differentiation ,cytotoxic functions and intracellular cytokines secreting of HIV specific CTL ex vivo by MTT assay combined flow cytometry. ResultsvMIP-Ⅱ of high dose(125μg/Kg) could accelerate proliferation of SIV specific T lymphocytes, these cells treated with vMIP-Ⅱ after 9 weeks were more proliferous than 5 weeks. There were differences between deal with vMIP-Ⅱ groups and normal control groups in CD8~+T lymphocytes quantities and their subsets differentiation (P< 0.05 ) ,and there was no difference between vMIP-Ⅱ group and positive control (P< 0.05). vMIP-Ⅱ did not affect the proliferation and differentiation of HIV specific CTL constructed in vitro (P>0.05) ,but it could promote the expression of Fas on HIVspecific CTL and secretion of IFN-y (P<0.05) ,it couldn't affect the secretion of IL-4(JP>0.05) . ConclusionsvMiP-II could regulate cellular immunity of SIV/HIV specific CD8+T lymphocytes through combining with multi-chemokine receptors that expressed on those cells.One side, vMIP- II could accelerate SIV specific CD8+T lymphocytes to proliferate and facilitate these cells to polarize to CD8+CD28+T lymphocytes in vivo;on the other hand, vMIP-II could up-regulate HIV specific CTL immunity response in vitro.